



## Lipomics Technologies Launches Insight™ Metabolic Pathway Maps and Signature™ Flux Equations

WEST SACRAMENTO, Calif., September 2, 2003 — Lipomics Technologies Inc., a privately owned company that specializes in lipid metabolite research and analytical services, today announced two new products for metabolic research, Lipomics Insight™ and Signature™.

Lipomics Insight™ metabolic pathway maps assemble the results of TrueMass® lipid metabolite measurements, with Signature™ flux equations, to generate an informative graphical representation of a lipid metabolism. An Insight map can be used, for example, to evaluate the metabolic effects of drug compounds or to establish the mechanism of unusual drug response. Insight pathway maps launched today include those representing lipid metabolism in plasma or serum, liver, adipose, muscle and heart tissue as well as maps for specific metabolic processes including lipogenesis and essential fatty acid metabolism.

Signature™ equations use TrueMass® data to estimate the steady-state flux of lipid metabolites through key lipid metabolism pathways. Signature equations have been developed and empirically tested using the company's extensive database experimental subjects and its institutional knowledge of lipid metabolism.

TrueMass® analysis, Lipomics core product, is a proprietary system for quantifying hundreds of lipid metabolites in biological sample.

Insight™ and Signature™ products are available exclusively to Lipomics research alliance partners.

### About Lipomics Technologies, Inc.

Lipomics develops tools for drug discovery and patient monitoring based on its proprietary technologies for lipid metabolite analysis and data interpretation. The company generates knowledge of lipid metabolism by combining quantitative measurements of lipid metabolites in plasma or tissue samples with proprietary algorithms for mapping the resulting profiles to biochemical pathways. In partnership with pharmaceutical companies, Lipomics uses its technology to speed drug discovery processes, improve clinical trial stratification, reduce late-stage drug attrition, and to develop early tests for monitoring drug response. The Company's products and technologies include TrueMass® lipid analysis platform, Signature™ algorithms for linking lipomic profiles to biochemical pathways, Surveyor™ data visualization software, and Insight™ software for assembling metabolite concentration and enzyme flux data into a quantitative pathway map.

TrueMass® is a registered US trademark of Lipomics Technologies, Inc.

Lipomics Insight™ and Signature™ are trademarks of Lipomics Technologies Inc. Recently updated information, news postings and resources for understanding lipids and their role in health and disease can be found online at [www.lipomics.com](http://www.lipomics.com).

# # #

EDITORIAL CONTACTS:

Sarina Chohan, Lipomics  
(916) 371-7974  
[schohan@lipomics.com](mailto:schohan@lipomics.com)

Agency Contact

Doug Forsyth, Alchymia Communications  
(541) 482-8744  
[df@alchymiacomm.com](mailto:df@alchymiacomm.com)